What Alterity Therapeutics Ltd does.

Our technology has been developed over an extended period and continues to develop through the collaborative efforts of highly regarded scientists, company employees as well as representatives of research institutions in this field. Since completing our initial public offering and listing process of our ordinary shares on the ASX on March 28, 2000, we have concentrated our resources toward the pursuit of neurological diseases and creation of a chemical library of proprietary molecules.

Currently, our research and clinical development efforts are primarily focused on Parkinson’s disease and related disorders where iron dysregulation and protein aggregation are implicated in disease pathogenesis. We are identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing the excess labile iron that contributes to the pathologic process.

Our clinical development program is currently focused on MSA, a rare Parkinsonian disorder with no approved treatments that address the underlying pathology of the disease. We have also conducted a Natural History Study in MSA and have a preclinical program in Parkinson’s disease. In addition, we have a robust discovery platform developing compounds from different chemical scaffolds in our chemical library.

Revenue and profit, by fiscal year.

More on ATHE.

• Alterity Therapeutics Ltd summary
• Alterity Therapeutics Ltd financial statements
• Alterity Therapeutics Ltd key metrics
• Alterity Therapeutics Ltd health scores and style box
• Alterity Therapeutics Ltd earnings
• Alterity Therapeutics Ltd dividends
• Alterity Therapeutics Ltd valuation
• Alterity Therapeutics Ltd ownership and insiders
• Alterity Therapeutics Ltd peers

Figures from Alterity Therapeutics Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.